INIrina Naguibneva

Irina Naguibneva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Irina Naguibneva has a total of 63 co-authors. Here are the top co-authors by number of shared publications:

  • Benjamin Uzan

    Laboratoire des cellules Souches Hematopoietiques et des Leucemies, Equipe Niche et Cancer dans l'Hematopoiese, UMR1274-E008, INSERM, CEA

    3 shared publications
  • Françoise Pflumio

    Université de Paris, Institut National de la Santé et de la Recherche Médicale (INSERM), Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Stabilité Génétique Cellules Souches et Radiations, Fontenay-aux-Roses, France

    3 shared publications
  • Aissa Benyoucef

    Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Radiobiologie Cellulaire et Moléculaire, Laboratoire des Cellules Souches Hématopoïétiques et Leucémiques, Equipe Labellisée Ligue Contre le Cancer, Unité Mixte de Recherche (UMR) 967 Stabilité génomique, cellules souches et radiations, Fontenay-aux-Roses, France

    2 shared publications
  • Annick Harel-Bellan

    Laboratory of Molecular Immunoregulation, National Cancer Institute, Frederick, MD 21701

    2 shared publications
  • Arnaud Petit

    Hopital Armand Trousseau, APHP.Sorbonne Université, Paris, France

    2 shared publications
  • Julien Calvo

    Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Radiobiologie Cellulaire et Moléculaire, Laboratoire des Cellules Souches Hématopoïétiques et Leucémiques, Equipe Labellisée Ligue Contre le Cancer, Unité Mixte de Recherche (UMR) 967 Stabilité génomique, cellules souches et radiations, Fontenay-aux-Roses, France

    2 shared publications

Latest Publications

  • Open Access

    High CD44 expression identifies rare chemoresistant leukemic cells endowed with enhanced E-Selectin binding in T-ALL

    by Julien Calvo, Irina Naguibneva, Anthony Kypraios, Benjamin Uzan, Baptiste Gaillard, Lea Bellenger L, Laurent Renou, Christophe Antoniewski, Helene Lapillone, Arnaud Petit, et al.

    T-cell acute lymphoblastic leukemia (T-ALL) is a hematopoietic malignancy characterized by an increased proliferation and incomplete maturation of T-cell progenitors. Despite therapeutic improvements, relapses are often of bad prognosis. Therapeutic vulnerabilities and chemoresistance mechanisms arising from cell plasticity induced by the bone marrow (BM) microenvironment remain an important field of investigation. Employing single cell RNA sequencing (scRNAseq) of human T-ALL cells recovered from adipocyte-rich and -poor BM, a distinct leukemic stem cell (LSC) population defined by quiescence and elevated CD44 level (Ki67 neg/low CD44 high ) expression is identified in both territories. In vivo chemotherapy demonstrated that the LSC population evades drug treatment. Patient sample analyses confirmed the presence of Ki67 neg/low CD44 high LSC both at diagnosis and relapse that displayed a specific transcriptomic signature. Interestingly, the intense expression of CD44 in T-ALL Ki67 neg/low LSC was associated with E-selectin binding. Importantly, when 39 human T-ALL samples were analyzed, the E-selectin binding ability was found significantly higher in Relapse/Refractory compared to drug-sensitive patients. These findings characterize a T-ALL LSC population with chemoresistant properties and shade light on new strategies for prognostic stratification while opening avenues for novel therapeutic options.

  • Open Access

    Hypoxia favors chemoresistance in T-ALL through an HIF1α-mediated mTORC1 inhibition loop

    by Lucine Fahy, Julien Calvo, Sara Chabi, Laurent Renou, Charly Le Maout, Sandrine Poglio, Thierry Leblanc, Arnaud Petit, André Baruchel, Paola Ballerini, et al.

    Resistance to chemotherapy, a major therapeutic challenge in the treatment of T-cell acute lymphoblastic leukemia (T-ALL), can be driven by interactions between leukemic cells and the microenvironment that promote survival of leukemic cells. The bone marrow, an important leukemia niche, has low oxygen partial pressures that highly participate in the regulation of normal hematopoiesis. Here we show that hypoxia inhibits T-ALL cell growth by slowing down cell cycle progression, decreasing mitochondria activity, and increasing glycolysis, making them less sensitive to antileukemic drugs and preserving their ability to initiate leukemia after treatment. Activation of the mammalian target of rapamycin (mTOR) was diminished in hypoxic leukemic cells, and treatment of T-ALL with the mTOR inhibitor rapamycin in normoxia mimicked the hypoxia effects, namely decreased cell growth and increased quiescence and drug resistance. Knocking down (KD) hypoxia-induced factor 1α (HIF-1α), a key regulator of the cellular response to hypoxia, antagonized the effects observed in hypoxic T-ALL and restored chemosensitivity. HIF-1α KD also restored mTOR activation in low O2 concentrations, and inhibiting mTOR in HIF1α KD T-ALL protected leukemic cells from chemotherapy. Thus, hypoxic niches play a protective role of T-ALL during treatments. Inhibition of HIF-1α and activation of the mTORC1 pathway may help suppress the drug resistance of T-ALL in hypoxic niches.


  • Open Access

    Homeobox protein TLX3 activates miR-125b expression to promote T-cell acute lymphoblastic leukemia

    by Laurent Renou, Pierre-Yves Boelle, Caroline Deswarte, Salvatore Spicuglia, Aissa Benyoucef, Julien Calvo, Benjamin Uzan, Mohamed Belhocine, Agata Cieslak, Judith Landman-Parker, et al.

    Key Points: TLX3 transactivates LINC00478, the host gene of oncogenic miR-125b-2 in T-ALL. TLX3 and miR-125b contribute to the differentiation arrest and the expansion of transformed T cells.


  • Open Access

    Age-Associated Decrease of the Histone Methyltransferase SUV39H1 in HSC Perturbs Heterochromatin and B Lymphoid Differentiation

    by Dounia Djeghloul, Klaudia Kuranda, Isabelle Kuzniak, Daniela Barbieri, Irina Naguibneva, Caroline Choisy, Jean-Christophe Bories, Christine Dosquet, Marika Pla, Valérie Vanneaux, et al.


  • Open Access

    The SCL/TAL1 Transcription Factor Represses the Stress Protein DDiT4/REDD1 in Human Hematopoietic Stem/Progenitor Cells

    by Aissa Benyoucef, Julien Calvo, Laurent Renou, Marie-Laure Arcangeli, Anita van Den Heuvel, Sophie Amsellem, Maryam Mehrpour, Jerome Larghero, Eric Soler, Irina Naguibneva, et al.

    Hematopoietic stem/progenitor cells (HSPCs) are regulated through numerous molecular mechanisms that have not been interconnected. The transcription factor stem cell leukemia/T-cell acute leukemia 1 (TAL1) controls human HSPC but its mechanism of action is not clarified. In this study, we show that knockdown (KD) or short-term conditional over-expression (OE) of TAL1 in human HSPC ex vivo, respectively, blocks and maintains hematopoietic potentials, affecting proliferation of human HSPC. Comparative gene expression analyses of TAL1/KD and TAL1/OE human HSPC revealed modifications of cell cycle regulators as well as previously described TAL1 target genes. Interestingly an inverse correlation between TAL1 and DNA damage-induced transcript 4 (DDiT4/REDD1), an inhibitor of the mammalian target of rapamycin (mTOR) pathway, is uncovered. Low phosphorylation levels of mTOR target proteins in TAL1/KD HSPC confirmed an interplay between mTOR pathway and TAL1 in correlation with TAL1-mediated effects of HSPC proliferation. Finally chromatin immunoprecipitation experiments performed in human HSPC showed that DDiT4 is a direct TAL1 target gene. Functional analyses showed that TAL1 represses DDiT4 expression in HSPCs. These results pinpoint DDiT4/REDD1 as a novel target gene regulated by TAL1 in human HSPC and establish for the first time a link between TAL1 and the mTOR pathway in human early hematopoietic cells. Stem Cells 2015;33:2268–2279


  • MiRNAs in skeletal muscle differentiation

    by Irina Naguibneva, Anna Polesskaya, Annick Harel-Bellan

  • Micro-ARNs et différenciation musculaire

    by Irina Naguibneva, Anna Polesskaya, Maya Ameyar-Zazoua, Mouloud Souidi, Reguina Groisman, Sylvain Cuvellier, Slimane Ait-Si-Ali, Linda L. Pritchard, Annick Harel-Bellan

    Deciphering the mechanisms underlying skeletal muscle differentiation in mammals is an important challenge. Cell differentiation involves complex pathways regulated at both transcriptional and post-transcriptional levels. Recent observations have revealed the importance of small (20-25 base pairs) non-coding RNAs (microRNAs or miRNAs) that are expressed in both lower organisms and in mammals. miRNAs modulate gene expression by affecting mRNA translation or stability. In lower organisms, miRNAs are essential for cell differentiation during development; some miRNAs are involved in maintenance of the differentiated state. We have shown that miR-181, a microRNA that is strongly upregulated during differentiation, participates in establishing the muscle phenotype. Moreover, our results suggest that miR-181 downregulates the homeobox protein Hox-A11 (a repressor of the differentiation process), thus establishing a functional link between miR-181 and the complex process of mammalian skeletal muscle differentiation. Therefore, miRNAs can be involved in the establishment of a differentiated phenotype - even when they are not expressed in the corresponding fully differentiated tissue.